uniQure N.V. (NASDAQ:QURE) Short Interest Down 31.4% in October

uniQure N.V. (NASDAQ:QURE) was the target of a significant decrease in short interest in the month of October. As of October 15th, there was short interest totaling 7,570,000 shares, a decrease of 31.4% from the September 30th total of 11,030,000 shares. Currently, 14.5% of the company’s stock are sold short. Based on an average daily volume of 3,220,000 shares, the days-to-cover ratio is presently 2.4 days. Based on an average daily volume of 3,220,000 shares, the days-to-cover ratio is presently 2.4 days. Currently, 14.5% of the company’s stock are sold short.

Analysts Set New Price Targets

A number of research firms recently weighed in on QURE. The Goldman Sachs Group raised their price target on shares of uniQure from $13.00 to $56.00 and gave the company a “neutral” rating in a report on Thursday, September 25th. Chardan Capital raised their price target on shares of uniQure from $35.00 to $76.00 and gave the company a “buy” rating in a report on Thursday, September 25th. Royal Bank Of Canada reaffirmed an “outperform” rating on shares of uniQure in a report on Wednesday, September 24th. Guggenheim raised their price target on shares of uniQure from $28.00 to $95.00 and gave the company a “buy” rating in a report on Thursday, September 25th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of uniQure in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, uniQure currently has an average rating of “Moderate Buy” and an average target price of $71.75.

uniQure Trading Down 0.3%

NASDAQ QURE opened at $67.69 on Friday. The company has a debt-to-equity ratio of 1.53, a current ratio of 9.98 and a quick ratio of 9.98. The company has a market capitalization of $3.71 billion, a price-to-earnings ratio of -17.27 and a beta of 0.56. uniQure has a 12 month low of $5.35 and a 12 month high of $71.50. The company’s fifty day moving average price is $40.74 and its two-hundred day moving average price is $23.65.

Insiders Place Their Bets

In related news, CEO Matthew C. Kapusta sold 226,316 shares of the firm’s stock in a transaction on Wednesday, September 24th. The shares were sold at an average price of $41.46, for a total transaction of $9,383,061.36. Following the completion of the sale, the chief executive officer directly owned 651,454 shares of the company’s stock, valued at approximately $27,009,282.84. This trade represents a 25.78% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Christian Klemt sold 15,000 shares of the firm’s stock in a transaction on Friday, September 26th. The shares were sold at an average price of $55.00, for a total transaction of $825,000.00. Following the sale, the chief financial officer directly owned 217,730 shares of the company’s stock, valued at approximately $11,975,150. The trade was a 6.45% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 244,316 shares of company stock valued at $10,328,181. Company insiders own 4.79% of the company’s stock.

Hedge Funds Weigh In On uniQure

Several large investors have recently added to or reduced their stakes in QURE. Aberdeen Group plc boosted its holdings in shares of uniQure by 24.2% in the 2nd quarter. Aberdeen Group plc now owns 2,750,714 shares of the biotechnology company’s stock valued at $38,345,000 after buying an additional 535,163 shares during the period. Cubist Systematic Strategies LLC acquired a new position in shares of uniQure in the 1st quarter valued at about $2,562,000. OMERS ADMINISTRATION Corp acquired a new position in shares of uniQure in the 1st quarter valued at about $152,000. KLP Kapitalforvaltning AS acquired a new position in shares of uniQure in the 2nd quarter valued at about $117,000. Finally, Russell Investments Group Ltd. acquired a new position in shares of uniQure in the 1st quarter valued at about $3,218,000. 78.83% of the stock is currently owned by institutional investors.

uniQure Company Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.